{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:19:22Z","timestamp":1773008362314,"version":"3.50.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008199","name":"RTI International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008199","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jval.2020.03.015","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T07:29:20Z","timestamp":1595662160000},"page":"1096-1108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Economic Evaluation of Interventions to Address Opioid Misuse: A Systematic Review of Methods Used in Simulation Modeling Studies"],"prefix":"10.1016","volume":"23","author":[{"given":"Carolina","family":"Barbosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William N.","family":"Dowd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Zarkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2020.03.015_bib3","first-page":"235","article-title":"Focus: addiction: reducing fatal opioid overdose: prevention, treatment and harm reduction strategies","volume":"88","author":"Hawk","year":"2015","journal-title":"Yale J Biol Med"},{"issue":"15","key":"10.1016\/j.jval.2020.03.015_bib4","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/archinternmed.2012.2374","article-title":"Prescription drug abuse and DEA-sanctioned drug take-back events: characteristics and outcomes in rural Appalachia","volume":"172","author":"Gray","year":"2012","journal-title":"Arch Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.jval.2020.03.015_bib5","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1111\/j.1526-4637.2011.01128.x","article-title":"Project Lazarus: community-based overdose prevention in rural North Carolina","volume":"12","author":"Albert","year":"2011","journal-title":"Pain Med"},{"issue":"11","key":"10.1016\/j.jval.2020.03.015_bib6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/M17-3074","article-title":"Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review","volume":"168","author":"Fink","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.jval.2020.03.015_bib7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/add.13860","article-title":"Impact of prescription drug monitoring programs (PDMPs) on Opioid utilization among medicare beneficiaries in 10 US states","volume":"112","author":"Moyo","year":"2017","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.jval.2020.03.015_bib8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1377\/hlthaff.2015.1496","article-title":"Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates","volume":"35","author":"Patrick","year":"2016","journal-title":"Health Aff"},{"issue":"2","key":"10.1016\/j.jval.2020.03.015_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harv Rev Psychiatry"},{"issue":"3","key":"10.1016\/j.jval.2020.03.015_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jval.2020.03.015_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.7326\/M18-1397","article-title":"Overdose prevention through medical treatment of opioid use disorders","volume":"169","author":"Volkow","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jval.2020.03.015_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1802741","article-title":"Primary care and the opioid-overdose crisis\u2014buprenorphine myths and realities","volume":"379","author":"Wakeman","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2020.03.015_bib13","first-page":"91","article-title":"A\u00a0systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"J\u00a0Addict Med"},{"issue":"5","key":"10.1016\/j.jval.2020.03.015_bib14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/add.13265","article-title":"Effectiveness of Scotland's national naloxone programme for reducing opioid-related deaths: a before (2006\u201310) versus after (2011\u201313) comparison","volume":"111","author":"Bird","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jval.2020.03.015_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.drugalcdep.2018.07.017","article-title":"The changing landscape of naloxone availability in the United States, 2011-2017","volume":"191","author":"Freeman","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jval.2020.03.015_bib16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.drugalcdep.2017.05.001","article-title":"Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids\u2014conception and maturation","volume":"178","author":"McDonald","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.jval.2020.03.015_bib17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.amepre.2017.06.010","article-title":"Addressing the nation\u2019s opioid epidemic: lessons from an unsanctioned supervised injection site in the US","volume":"53","author":"Kral","year":"2017","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jval.2020.03.015_bib18","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"10.1016\/j.jval.2020.03.015_bib19","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2017"},{"key":"10.1016\/j.jval.2020.03.015_bib20","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"3","key":"10.1016\/j.jval.2020.03.015_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W","article-title":"Modelling in economic evaluation: an unavoidable fact of life","volume":"6","author":"Buxton","year":"1997","journal-title":"Health Econ"},{"issue":"3","key":"10.1016\/j.jval.2020.03.015_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0167-6296(98)00039-3","article-title":"The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies","volume":"18","author":"Claxton","year":"1999","journal-title":"J\u00a0Health Econ"},{"issue":"4","key":"10.1016\/j.jval.2020.03.015_bib23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1524-4733.2005.00033.x","article-title":"Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?","volume":"8","author":"Sculpher","year":"2005","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2020.03.015_bib24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40273-016-0400-5","article-title":"Economic evaluations of opioid use disorder interventions","volume":"34","author":"Murphy","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2020.03.015_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","article-title":"A\u00a0typology of reviews: an analysis of 14 review types and associated methodologies","volume":"26","author":"Grant","year":"2009","journal-title":"Health Info Libr J"},{"issue":"1","key":"10.1016\/j.jval.2020.03.015_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.jval.2020.03.015_bib27","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jval.2020.03.015_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated health economic evaluation reporting standards (cheers)\u2014explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.03.015_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1471-2288-12-168","article-title":"Reporting guidelines for modelling studies","volume":"12","author":"Bennett","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.jval.2020.03.015_bib30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00019053-199814030-00003","article-title":"Reporting format for economic evaluation","volume":"14","author":"Nuijten","year":"1998","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2020.03.015_bib31","doi-asserted-by":"crossref","DOI":"10.3310\/hta11060","article-title":"Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation","volume":"11","author":"Adi","year":"2007","journal-title":"Health Technol Assess"},{"issue":"7","key":"10.1016\/j.jval.2020.03.015_bib32","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/add.14171","article-title":"Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the Salome randomized clinical trial","volume":"113","author":"Bansback","year":"2018","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.jval.2020.03.015_bib33","first-page":"893","article-title":"Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder","volume":"20","author":"Carter","year":"2017","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jval.2020.03.015_bib34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.drugalcdep.2018.08.003","article-title":"Cost-effectiveness of naloxone kits in secondary schools","volume":"192","author":"Cipriano","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"10.1016\/j.jval.2020.03.015_bib35","first-page":"1051","article-title":"Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities","volume":"16","author":"Coffin","year":"2013","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2020.03.015_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-158-1-201301010-00003","article-title":"Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal","volume":"158","author":"Coffin","year":"2013","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.jval.2020.03.015_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11090","article-title":"Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.jval.2020.03.015_bib38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/08897077.2015.1010031","article-title":"Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence","volume":"36","author":"Jackson","year":"2015","journal-title":"Subst Abus"},{"issue":"7","key":"10.1016\/j.jval.2020.03.015_bib39","first-page":"740","article-title":"Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study","volume":"20","author":"Kenworthy","year":"2017","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2020.03.015_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/15360288.2015.1135847","article-title":"Office-based buprenorphine versus clinic-based methadone: a cost-effectiveness analysis","volume":"30","author":"King","year":"2016","journal-title":"J\u00a0Pain Palliat Care Pharmacother"},{"issue":"1","key":"10.1016\/j.jval.2020.03.015_bib41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M17-0611","article-title":"Cost-effectiveness of publicly funded treatment of opioid use disorder in California","volume":"168","author":"Krebs","year":"2018","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.jval.2020.03.015_bib42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jval.2017.07.014","article-title":"Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the United Kingdom","volume":"21","author":"Langham","year":"2018","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2020.03.015_bib43","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1360-0443.2004.00728.x","article-title":"Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification","volume":"99","author":"Masson","year":"2004","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.jval.2020.03.015_bib44","doi-asserted-by":"crossref","first-page":"E317","DOI":"10.1503\/cmaj.110669","article-title":"Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment","volume":"184","author":"Nosyk","year":"2012","journal-title":"CMAJ"},{"issue":"6","key":"10.1016\/j.jval.2020.03.015_bib45","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","article-title":"Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care","volume":"27","author":"Schackman","year":"2012","journal-title":"J\u00a0Gen Intern Med"},{"issue":"3","key":"10.1016\/j.jval.2020.03.015_bib46","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1360-0443.2011.03656.x","article-title":"Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis","volume":"107","author":"Stephen","year":"2012","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.jval.2020.03.015_bib47","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/S2468-2667(17)30006-3","article-title":"Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study","volume":"2","author":"Uyei","year":"2017","journal-title":"Lancet Public Health"},{"issue":"11","key":"10.1016\/j.jval.2020.03.015_bib48","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/hec.999","article-title":"Benefits and costs of methadone treatment: results from a lifetime simulation model","volume":"14","author":"Zarkin","year":"2005","journal-title":"Health Econ"},{"issue":"2","key":"10.1016\/j.jval.2020.03.015_bib49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2017.12.009","article-title":"A\u00a0health economics approach to U.S. value assessment frameworks\u2014summary and recommendations of the ISPOR Special Task Force Report [7]","volume":"21","author":"Garrison","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.03.015_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2018.6072","article-title":"QALYs in 2018\u2014advantages and concerns","author":"Neumann","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2020.03.015_bib51","series-title":"Guide to Methods of Technology Appraisal","year":"2004"},{"issue":"3","key":"10.1016\/j.jval.2020.03.015_bib52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol-a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"issue":"9","key":"10.1016\/j.jval.2020.03.015_bib53","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hec.866","article-title":"A\u00a0Comparison of the EQ-5D and SF-6D across seven patient groups","volume":"13","author":"Brazier","year":"2004","journal-title":"Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2020.03.015_bib54","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1477-7525-4-90","article-title":"A\u00a0pilot internet \u201cValue of Health\u201d panel: recruitment, participation and compliance","volume":"4","author":"Stein","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"13","key":"10.1016\/j.jval.2020.03.015_bib55","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jval.2020.03.015_bib56","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2020.03.015_bib57","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good\u00a0Research Practices Task Force\u20137","volume":"32","author":"Eddy","year":"2012","journal-title":"Med Decis Making"},{"issue":"12","key":"10.1016\/j.jval.2020.03.015_bib58","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/hec.1148","article-title":"A\u00a0taxonomy of model structures for economic evaluation of health technologies","volume":"15","author":"Brennan","year":"2006","journal-title":"J\u00a0Health Econ"},{"key":"10.1016\/j.jval.2020.03.015_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jval.2012.06.016","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2","volume":"15","author":"Roberts","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2020.03.015_bib60","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/add.13195","article-title":"Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada","volume":"111","author":"Enns","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jval.2020.03.015_bib61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.drugpo.2018.02.008","article-title":"Effects of naloxone distribution to likely bystanders: results of an agent-based model","volume":"55","author":"Keane","year":"2018","journal-title":"Int J Drug Policy"},{"issue":"6","key":"10.1016\/j.jval.2020.03.015_bib62","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3109\/00952990.2015.1043435","article-title":"Dynamic model of nonmedical opioid use trajectories and potential policy interventions","volume":"41","author":"Wakeland","year":"2015","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2020.03.015_bib63","doi-asserted-by":"crossref","first-page":"74S","DOI":"10.1177\/1090198113492767","article-title":"Modeling the impact of simulated educational interventions on the use and abuse of pharmaceutical opioids in the United States: a report on initial efforts","volume":"40","author":"Wakeland","year":"2013","journal-title":"Health Educ Behav"},{"issue":"7","key":"10.1016\/j.jval.2020.03.015_bib64","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2105\/AJPH.90.7.1100","article-title":"HIV transmission and the cost-effectiveness of methadone maintenance","volume":"90","author":"Zaric","year":"2000","journal-title":"Am J Public Health"},{"issue":"10","key":"10.1016\/j.jval.2020.03.015_bib65","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2020.03.015_bib66","series-title":"Cost-Effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"issue":"15","key":"10.1016\/j.jval.2020.03.015_bib67","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the Panel on Cost-Effectiveness in Health and Medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jval.2020.03.015_bib68","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/add.13219","article-title":"Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US Population","volume":"111","author":"Wittenberg","year":"2016","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.jval.2020.03.015_bib69","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00019053-200624110-00003","article-title":"Using value of information analysis to prioritise health research - some lessons from recent UK experience","volume":"24","author":"Claxton","year":"2006","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2020.03.015_bib70","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/0272989X04263162","article-title":"Expected value of sample information calculations in medical decision modeling","volume":"24","author":"Ades","year":"2004","journal-title":"Med Decis Making"},{"issue":"5","key":"10.1016\/j.jval.2020.03.015_bib71","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0272989X12454577","article-title":"Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1","volume":"32","author":"Caro","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2020.03.015_bib72","author":"Smart"},{"issue":"4","key":"10.1016\/j.jval.2020.03.015_bib73","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","article-title":"Advishe: a validation-assessment tool of health-economic models for decision makers and model users","volume":"34","author":"Vemer","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2020.03.015_bib74","article-title":"Prevention of prescription opioid misuse and projected overdose deaths in the United States","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jval.2020.03.015_bib75","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2105\/AJPH.2018.304590","article-title":"Modeling health benefits and harms of public policy responses to the US opioid epidemic","volume":"108","author":"Pitt","year":"2018","journal-title":"Am J Public Health"},{"issue":"9","key":"10.1016\/j.jval.2020.03.015_bib76","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/add.14664","article-title":"Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic","volume":"114","author":"Irvine","year":"2019","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.jval.2020.03.015_bib77","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1503\/cmaj.080808","article-title":"The cost-effectiveness of Vancouver's supervised injection facility","volume":"179","author":"Bayoumi","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.jval.2020.03.015_bib78","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugpo.2017.06.003","article-title":"US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations","volume":"46","author":"Unick","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"6","key":"10.1016\/j.jval.2020.03.015_bib79","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.amepre.2017.06.009","article-title":"Geographic variation in opioid and heroin involved drug poisoning mortality rates","volume":"53","author":"Ruhm","year":"2017","journal-title":"Am J Prev Med"},{"issue":"6","key":"10.1016\/j.jval.2020.03.015_bib80","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder","volume":"2","author":"Haffajee","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jval.2020.03.015_bib81","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/1475-6773.12686","article-title":"Geographic disparities in availability of opioid use disorder treatment for medicaid enrollees","volume":"53","author":"Abraham","year":"2018","journal-title":"Health Serv Res"},{"key":"10.1016\/j.jval.2020.03.015_bib82","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drugpo.2018.04.011","article-title":"Opioid-related mortality in rural America: geographic heterogeneity and intervention strategies","volume":"57","author":"Rigg","year":"2018","journal-title":"Int J Drug Policy"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520320647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520320647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:21:13Z","timestamp":1761096073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520320647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1098301520320647"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.03.015","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluation of Interventions to Address Opioid Misuse: A Systematic Review of Methods Used in Simulation Modeling Studies","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}